Streetbeat News

Earnings

CZR

Caesars Entertainment (NASDAQ:CZR) reported Q4 earnings, beating estimates with an EPS of $0.1 against an expected -$0.04. Revenue increased by $4.00 million from the previous year. Despite beating last quarter's EPS estimate, the share price dropped by 1.05% the following day. Historical earnings data shows fluctuating performance over the past year.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:11 pm

CHK

Chesapeake Energy (NASDAQ:CHK) reported Q4 earnings with an EPS of $1.31, surpassing the estimate of $0.75 by 74.67%. However, revenue decreased by $2.18 billion from the same period last year. In the previous quarter, CHK beat the EPS estimate by $0.45, leading to a 0.96% increase in share price the following day. The company has shown a pattern of surpassing EPS estimates over the past four quarters.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

THAR

Tharimmune Inc (NASDAQ:THAR) completed its Phase 1 clinical trial for TH104, a transmucosal buccal film for chronic liver disease, showing safety and tolerability comparable to FDA-approved nalmefene. The trial's full data is expected in Q2 2024. Last quarter, Tharimmune closed an $11 million public offering to extend its cash runway into early 2025 for TH104's clinical readouts. THAR shares rose 0.26% to $0.39.

Portfolio Pulse from Vandana Singh

February 20, 2024 | 9:10 pm

WSC

WillScot Mobile Mini (NASDAQ:WSC) reported Q4 earnings with an EPS of $0.44, missing estimates by 15.38% against an expected $0.52. Revenue increased by $21.82 million from the previous year. The company's past earnings performance shows a mixed trend with occasional beats and misses. Last quarter, a slight beat in EPS was followed by an 8.77% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

CWK

Cushman & Wakefield (NYSE:CWK) reported Q4 earnings with a 12.5% beat on EPS estimates, reporting $0.45 versus the expected $0.4. However, revenue was down $95 million from the same period last year. Despite missing EPS estimates last quarter, CWK's share price increased by 8.7% the following day. The company's past earnings performance shows mixed results with both misses and beats on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

MFIN

Medallion Financial Corp. (NASDAQ:MFIN) reported Q4 earnings with an EPS of $0.6, missing estimates by 4.76% against an expected $0.63. Revenue increased by $7.55 million from the same period last year. In the previous quarter, MFIN beat EPS estimates and saw a 12.15% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

ENVX

Enovix Corporation (NASDAQ:ENVX) reported its Q4 earnings on February 20, 2024, missing estimated earnings by 3.7% with an EPS of $-0.28 versus an estimate of $-0.27. Revenue increased by $6.29 million from the same period last year. In the previous quarter, Enovix beat EPS estimates by $0.04, leading to a 14.75% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

MED

Medifast (NYSE:MED) reported Q4 earnings with an EPS of $1.09, beating estimates by 13.54% but with a revenue decrease of $146.23 million from the previous year. This follows a pattern of beating EPS estimates but experiencing a share price drop the next day, as seen in the last quarter.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

NEO

NeoGenomics (NASDAQ:NEO) reported Q4 earnings with a significant beat on estimated earnings, posting an EPS of $0.03 against an estimate of -$0.02, marking a 250% beat. Revenue increased by $16.85 million from the same period last year. The company has a history of beating EPS estimates, which in the past has led to a notable increase in share price the following day.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 9:10 pm

TDOC

Teladoc Health (TDOC) reported Q4 2023 GAAP EPS of $(0.17), surpassing the $(0.21) estimate by 19.05%. However, its quarterly sales of $660.50 million fell short of the $671.43 million estimate by 1.63%, marking a 3.57% year-over-year increase.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:10 pm